Index of reports
> Cases with Acute Myeloid Leukaemia (3)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Bicnu (Carmustine) where reactions include acute myeloid leukaemia. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Bicnu side effects in 60 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-09
Patient: 60 year old female
Reactions: Myelofibrosis, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Idiopathic Thrombocytopenic Purpura
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Alkeran
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Bicnu
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Cyclophosphamide
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Dexamethasone
Dosage: 4 years, intravenous (not otherwise specified)
Indication: Multiple Myeloma
Doxorubicin Hydrochloride
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Prednisone
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Velcade
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Start date: 2008-05-05
Velcade
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Start date: 2008-05-19
Velcade
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Start date: 2008-04-08
Vepesid
Dosage: intravenous (not otherwise sepcified)
Indication: Multiple Myeloma
Vincristine Sulfate
Dosage: intravenous (not otherwise specified)
Indication: Multiple Myeloma
Other drugs received by patient: Neupogen; Corticosteroids
Possible Bicnu side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01
Patient: female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Alkeran
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Bicnu
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Start date: 2008-04-08
Dexamethasone
Start date: 2008-06-01
End date: 2008-01-01
Dexamethasone
Indication: Multiple Myeloma
Start date: 2008-05-05
Dexamethasone
Start date: 2008-05-19
Doxorubicin Hydrochloride
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Prednisone
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Velcade
Indication: Multiple Myeloma
Start date: 2008-04-08
End date: 2008-09-01
Vepesid
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Vincristine
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Possible Bicnu side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01
Patient: female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Alkeran
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Bicnu
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Indication: Multiple Myeloma
Start date: 2004-01-01
End date: 2008-01-01
Dexamethasone
Start date: 2008-04-08
End date: 2008-09-01
Doxorubicin Hydrochloride
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Prednisone
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Velcade
Indication: Multiple Myeloma
Start date: 2008-04-08
End date: 2008-06-01
Vepesid
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Vincristine
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
|